Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Minority Interest (2016)

United Therapeutics' Minority Interest history spans 8 years, with the latest figure at $10.9 million for Q4 2016.

  • For Q4 2016, Minority Interest changed 0.0% year-over-year to $10.9 million; the TTM value through Dec 2016 reached $10.9 million, changed 0.0%, while the annual FY2016 figure was $10.9 million, 0.0% changed from the prior year.
  • Minority Interest for Q4 2016 was $10.9 million at United Therapeutics, roughly flat from $10.9 million in the prior quarter.
  • Across five years, Minority Interest topped out at $10.9 million in Q4 2015 and bottomed at $10.9 million in Q1 2012.
  • The 5-year median for Minority Interest is $10.9 million (2012), against an average of $10.9 million.
  • The largest annual shift saw Minority Interest changed 0.0% in 2012 before it rose 0.17% in 2015.
  • A 5-year view of Minority Interest shows it stood at $10.9 million in 2012, then changed by 0.0% to $10.9 million in 2013, then changed by 0.0% to $10.9 million in 2014, then rose by 0.17% to $10.9 million in 2015, then changed by 0.0% to $10.9 million in 2016.
  • Per Business Quant, the three most recent readings for UTHR's Minority Interest are $10.9 million (Q4 2016), $10.9 million (Q4 2015), and $10.9 million (Q3 2015).